Development of a technology platform for large-scale clinical grade production of DC

Cytotherapy

Volumn 6, Issue 4, 2004, Pages 363-371

  Adamson, L ^a   Palmborg, A ^a   Svensson, A ^b   Lundqvist, A ^a   Hansson, M ^b   Kiessling, R ^a   Masucci, G ^a   Mellstedt, H ^a   Pisa, Pavel ^a,b  

^a Karolinska Krankenhaus   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Culture bags; Elutriation; Leukapheresis; Maturation; Monocytes; Poly I:C

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 4; PROTEIN P70; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CELL MATURATION; CELL SELECTION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DENDRITIC CELL; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOGENICITY; LEUKAPHERESIS; MALIGNANT NEOPLASTIC DISEASE; MONOCYTE; PHAGOCYTOSIS; PRACTICE GUIDELINE; THAWING; VALIDATION PROCESS;

EID: 4544250879     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240410004934     Document Type: Article

References (25)

1. Steinman RM. Dendritic cells and immune-based therapies. J Exp Hematol 1996;24:859-62.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
3. Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene 2000;19:6673-9.
4. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000;18:245-73.
5. Lundqvist A, Pisa P. Gene modified dendritic cells for immunotherapy against cancer. Med Oncol 2002;19:197-211.
6. Kono K, Takahashi A, Sugai H et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002;8:3394-400.
7. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
8. Romani N, Reider D, Heuer M et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-51.
9. Morse MA, Mosca PJ, Clay TM et al. Dendritic cell maturation in active immunotherapy strategies. Expert Opin Biol Ther 2002;2:35-43.
10. Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243-51.
11. Bernhard H, Disis ML, Heimfeld S et al. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995;55:1099-104.
12. Pretlow TG II, Pretlow TP. Centrifugal elutriation (counter-streaming centrifugation) of cells. Cell Biophys 1979;1:195-210.
13. Svensson A, Engervall P, Soderstrom T et al. PBSC harvests individually optimized by using pre-collection CD34(+) values and on-line flow cytometric analysis of the mononuclear cell enrichment. Cyrotherapy 1999;1:165-74.
14. European Pharmacopoeia, 4th Edition 2002;140-7.
15. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000;1:199-205.
16. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments]. Nature Med 1998;4:328-32.
17. Murphy G, Tjoa B, Ragde H et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-80.
18. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:409-17.
19. Svane IM, Soot ML, Buus S et al. Clinical application of dendritic cells in cancer vaccination therapy. Apmis 2003;111:818-34.
20. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med 2001;7:761-5.
21. Devitt A, Moffatt OD, Raykundalia C et al. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998;392:505-9.
22. Bernard J, Ittelet D, Christoph A et al. Adherent-free generation of functional dendritic cells from purified blood monocytes in view of potential clinical use. Hematol Cell Ther 1998;40:17-26.
23. Guyre CA, Fisher JL, Waugh MG et al. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells of clinical applications. J Immunol Methods 2002;262:85-94.
24. Wong EC, Maher VE, Hines K et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001;3:19-29.
25. Wong EC, Lee SM, Hines K et al. Development of a closed-system process for clinical-scale generation of DCs: evaluation of two monocyte-enrichment methods and two culture containers. Cytotherapy 2002;4:65-76.